Aerie pharmaceuticals says withdrawing 2020 guidance for net revenues and net cash used in operations

Aerie pharmaceuticals provides 2020 company and guidance update associated with covid-19.aerie pharmaceuticals inc - withdrawing its 2020 guidance for net revenues and net cash used in operations.aerie pharmaceuticals inc - guidance will be updated when there is clarity going forward.aerie pharmaceuticals inc - regulatory review in europe of roclanda remains on track.aerie pharmaceuticals inc - has observed no disruptions to date in its supply chain for production of rhopressa and rocklatan.aerie pharmaceuticals inc - hopes to commence its phase 2b clinical study for dry eye candidate ar-15512 by end of 2020.aerie pharmaceuticals inc - from a pipeline perspective, aerie's early stage retina implant trials remain on track.
AERI Ratings Summary
AERI Quant Ranking